CMC(SH:600327)2023-04-27 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥909,421,991.74, representing a year-on-year increase of 5.96%[3] - The net profit attributable to shareholders decreased by 55.03% to ¥25,748,899.42 compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 66.08% to ¥13,401,626.32[3] - The basic and diluted earnings per share were both ¥0.029, reflecting a decrease of 55.03% year-on-year[4] - Net profit for Q1 2023 was ¥47,006,187.44, down from ¥91,493,981.47 in Q1 2022, indicating a decline of 48.7%[15] - The net profit for Q1 2023 was ¥27,099,128.83, a decrease of 60.9% compared to ¥69,320,742.86 in Q1 2022[16] - The net profit attributable to shareholders of the parent company was ¥25,748,899.42, down 55.1% from ¥57,257,514.55 in the previous year[16] - The total comprehensive income for Q1 2023 was ¥35,574,139.03, a decline of 48.6% from ¥69,108,867.60 in Q1 2022[16] - The basic and diluted earnings per share for Q1 2023 were both ¥0.029, compared to ¥0.065 in Q1 2022, representing a decrease of 55.4%[16] Cash Flow and Investments - The net cash flow from operating activities was ¥202,040,894.22, with no applicable year-on-year comparison[3] - Cash inflows from operating activities totaled ¥1,326,466,460.68, down 9.1% from ¥1,459,197,692.06 in the same period last year[18] - The net cash flow from operating activities was ¥202,040,894.22, a significant improvement from a net outflow of -¥26,218,840.44 in Q1 2022[18] - The net cash flow from investing activities was -¥124,328,006.74, compared to -¥156,026,125.89 in the previous year, indicating a reduced cash outflow[19] - The net cash flow from financing activities was ¥35,618,796.69, a recovery from a net outflow of -¥220,968,597.09 in Q1 2022[19] - The cash and cash equivalents at the end of Q1 2023 were ¥592,297,013.15, an increase from ¥1,168,196,437.06 at the end of Q1 2022[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,584,802,377.78, an increase of 1.67% from the end of the previous year[3] - Total assets as of March 31, 2023, amounted to ¥5,584,802,377.78, an increase from ¥5,492,937,354.40 at the end of December 2022[12] - Total liabilities increased to ¥2,146,990,296.58 in Q1 2023 from ¥2,091,401,736.16 in Q4 2022, reflecting a rise of 2.7%[12] - Non-current assets totaled ¥4,438,187,380.81 as of March 31, 2023, slightly down from ¥4,383,733,677.10 at the end of December 2022[11] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 47,361[6] - The equity attributable to shareholders increased by 1.08% to ¥3,237,093,377.02 compared to the end of the previous year[3] Operational Metrics - Operating costs for Q1 2023 were ¥857,333,793.24, up from ¥794,616,841.72 in Q1 2022, reflecting a rise of 7.9%[15] - The company reported non-recurring gains of ¥12,347,273.10, primarily from government subsidies and other income[4] - The decline in net profit was mainly due to reduced investment income from associates and the impact of negative goodwill from a medical business acquisition[4] - Accounts receivable rose to ¥142,043,210.53 in Q1 2023, up from ¥88,118,064.56 in Q4 2022, marking a significant increase of 60.9%[10] - Inventory decreased to ¥241,328,362.88 in Q1 2023 from ¥258,696,835.70 in Q4 2022, a reduction of 6.7%[10] - The company reported R&D expenses of ¥2,524,297.22 in Q1 2023, indicating ongoing investment in innovation[15]